Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA:
1
and their use in the treatment of diabetes and other conditions associated with elevated blood glucose.
Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
申请人:——
公开号:US20040167178A1
公开(公告)日:2004-08-26
Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.
Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
申请人:Erion D. Mark
公开号:US20080004226A1
公开(公告)日:2008-01-03
Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.